Bolt Biotherapeutics (BOLT) — Financial Flexibility Index

Latest as of December 2025: -0.24x

Bolt Biotherapeutics (BOLT) has a Financial Flexibility Index of -0.24x as of December 2025. Free cash flow of $-7.16 Million (operating CF $-7.16 Million minus capex $0.00) represents 0% of total liabilities ($30.24 Million). Check BOLT tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Financial Flexibility Index

-0.24x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-7.16 Million
Operating CF − Capex

Total Liabilities

$30.24 Million
USD

Capital Expenditures

$0.00
USD

Bolt Biotherapeutics Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Bolt Biotherapeutics across 8 annual periods. For the full cash flow conversion analysis, see BOLT cash generation efficiency.

Annual Financial Flexibility Index for Bolt Biotherapeutics (2018–2025)

Year-by-year free cash flow to debt coverage for Bolt Biotherapeutics. Explore BOLT operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -1.32x $-39.78 Million $-39.85 Million $30.24 Million ▲ +8.9%
2024 -1.44x $-61.25 Million $-61.29 Million $42.43 Million ▲ +2.0%
2023 -1.47x $-69.32 Million $-69.53 Million $47.04 Million ▼ -11.3%
2022 -1.32x $-74.55 Million $-76.50 Million $56.30 Million ▼ -39.4%
2021 -0.95x $-54.73 Million $-57.07 Million $57.60 Million ▼ -226.8%
2020 -0.29x $-44.05 Million $-47.31 Million $151.49 Million ▼ -6.1%
2019 -0.27x $-25.84 Million $-26.34 Million $94.29 Million ▲ +8.7%
2018 -0.30x $-9.58 Million $-9.87 Million $31.92 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities